Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified November 2014 by Hoffmann-La Roche
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: August 27, 2013
Last updated: November 3, 2014
Last verified: November 2014

This multicenter prospective observational study will evaluate the safety and ef ficacy of Avastin (bevacizumab) in routine clinical practice in patients with ad vanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary pe ritoneal cancer. Data will be collected from eligible patients until death, with drawal of consent, loss to follow-up, or study closure.

Ovarian Cancer, Peritoneal Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Indian Multicentric Open Label Prospective Post Marketing Surveillance Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Safety: Incidence of adverse events [ Time Frame: up to approximately 1.5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: up to approximately 1.5 years ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: up to approximately 1.5 years ] [ Designated as safety issue: No ]
  • Overall response rate (complete response + partial response) [ Time Frame: up to approximately 1.5 years ] [ Designated as safety issue: No ]
  • Clinical benefit rate (complete response + partial response + stable disease) [ Time Frame: up to approximately 1.5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: January 2015
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer initiated on therapy with Avastin


Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Prescribed to receive Avastin or already ongoing on treatment with Avastin for advanced/metastatic ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage IIIb, IIIc and IV) according to routine clinical practice

Exclusion Criteria:

  • Not eligible for treatment with Avastin according to the local prescribing information
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01932125

Contact: Reference Study ID Number: ML28446 888-662-6728 (U.S. Only)

Not yet recruiting
Bangalore, India, 560017
Not yet recruiting
Chennai, India, 600116
Not yet recruiting
Chennai, India, 600035
Not yet recruiting
Gujarat, India, 395010
Not yet recruiting
Hyderabad, India, 500034
Not yet recruiting
Kolkata, India, 700054
Not yet recruiting
Mumbai, India, 400020
Not yet recruiting
New Delhi, India, 110029
Not yet recruiting
New Delhi, India, 110060
Not yet recruiting
New Delhi, India, 110062
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Additional Information:
No publications provided

Responsible Party: Hoffmann-La Roche Identifier: NCT01932125     History of Changes
Other Study ID Numbers: ML28446
Study First Received: August 27, 2013
Last Updated: November 3, 2014
Health Authority: India: Indian Health Authority-DCGI (Drug Controller General of India)

Additional relevant MeSH terms:
Fallopian Tube Neoplasms
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Peritoneal Neoplasms
Abdominal Neoplasms
Digestive System Neoplasms
Endocrine Gland Neoplasms
Genital Neoplasms, Female
Neoplasms by Histologic Type
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Adnexal Diseases
Digestive System Diseases
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Gonadal Disorders
Peritoneal Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 20, 2014